MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation

ConclusionsWe identify common pathological findings in patients with LETM as first clinical presentation of MOG-EM which distinguishes it from other forms of LETM and should lead to testing for MOG-IgG in these cases.
Source: Journal of Neurology - Category: Neurology Source Type: research

Related Links:

  How are you handling the coronavirus pandemic? Most people are struggling right now, but for those of us with mental illness, these days can feel truly overwhelming. Fear, depression, isolation and loss of routine are just a few of the difficulties many of us are facing. In today’s podcast, Gabe and Jackie discuss what we can do right now to make things just a little better, and they share their personal hopes and fears for humanity once this pandemic subsides. You’re not alone — we’re all in this together. Join us for an important discussion on how we can handle this time of fear and unc...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Anxiety and Panic General LifeHelper Mental Health and Wellness Not Crazy Podcast Source Type: blogs
Publication date: Available online 18 March 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Hughes AM, Ponsonby A-L, Dear K, Dwyer T, Taylor BV, van der Mei I, Ausimmune Investigator Group, Lucas RM
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Vaccines have been traditionally developed with the presumption that they exert identical immunogenicity regardless of target population and that they provide protection solely against their target pathogen. However, it is increasingly appreciated that vaccines can have off-target effects and that vaccine immunogenicity can vary substantially with demographic factors such as age and sex. Bacille Calmette-Guérin (BCG), the live attenuated Mycobacterium bovis vaccine against tuberculosis (TB), represents a key example of these concepts. BCG vaccines are manufactured under different conditions across the globe generati...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Ocrelizumab has been recently approved for relapsing-remitting MS, demonstrating a dramatic effect on MRI and clinical parameters in 2 pivotal phase III trials.1 However, long-term B-cell depletion might lead to an increased susceptibility to infections and/or to their increased severity (a case of fulminant hepatitis due to enterovirus infection has been recently reported by our group).2 Finally, depletion of B-cell compartment might impair acquisition of long-term humoral immunologic memory (i.e. production of antigen-specific class G immunoglobulins [IgG]) and might reduce T-lymphocyte response because of the absence of...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Autonomic diseases, All Immunology, Parasitic infections, Viral infections, Class IV, Multiple sclerosis Clinical/Scientific Notes Source Type: research
AbstractModern disease-modifying therapies (DMTs) in multiple sclerosis (MS) have variable modes of action and selectively suppress or modulate the immune system. In this review, we summarize the predicted and intended as well as unwanted adverse effects on leukocytes in peripheral blood as a result of treatment with DMTs for MS. We link changes in laboratory tests to the possible therapeutic risks that include secondary autoimmunity, infections, and impaired response to vaccinations. Profound knowledge of the intended effects on leukocyte counts, in particular lymphocytes, explained by the mode of action, and adverse effe...
Source: Journal of Neurology - Category: Neurology Source Type: research
Authors: Pourcher V Abstract Patients with multiple sclerosis taking immunosuppressive therapy may be at risk of reactivating latent pathogens, community-acquired infections, worsening asymptomatic chronic infections, and contracting de novo infections. This risk was evaluated mainly in short-term clinical trials and few studies have investigated this risk in real-life settings. In clinical practice, this infectious risk should be evaluated when a multiple sclerosis diagnosis is made in order to propose specific follow-up or immunization as soon as possible and thus avoid contraindications or risk of lowered vaccin...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, it is necessary to pay attention to therapies acting on B lymphocytes as they could influence the antibody titer and efficacy of vaccination making the search for other markers of vaccine efficacy desirable such as cell-mediated immunity with proliferation and induction of memory T lymphocytes in response to viral glycoproteins.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Conclusion TBE vaccination showed good tolerability and was safe in patients with MS. MS disease activity was not increased, and annualized relapse rates decreased after vaccination. Vaccine response differs according to the underlying DMT. Trial registration ClinicalTrials.gov, clinicaltrials.gov, Identifier: NCT02275741.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Viral infections, All Clinical trials, Multiple sclerosis Article Source Type: research
AbstractPatients with multiple sclerosis (MS) are at increased risk of infections and related worsening of neurological function. Influenza infection has been associated with increased risk of various neurological complications. We conducted a population-based registry study to investigate the risk of acute hospitalization of MS patients in relation to influenza infection or pandemic vaccination in Norway. The entire Norwegian population in the years 2008 –2014 was defined as our study population (N = 5,219,296). Information on MS diagnosis, influenza infection and vaccination were provided by Norwegian...
Source: European Journal of Epidemiology - Category: Epidemiology Source Type: research
More News: Allergy & Immunology | Brain | Multiple Sclerosis | Neurology | Vaccines